Table 2.
G protein-coupled receptor-targeted antibody candidates
| Receptor target | Company | Disease indication | Status |
| C3aR | Human Genome Sciences | Asthma | Early stage (patent) |
| C5aR | G2 Therapies/Novo Nordisk | Rheumatoid arthritis, systemic lupus erythematosus | Phase 1 |
| FPRL | Yes Biotech (Anogen) | Alzheimer disease | Early stage |
| CXCR4 (MDX-1338) | Medarex/Bristol-Myers Squibb | Cancer (acute myeloid leukemia) | Phase 1 |
| (ALX-0651) | Ablynx | Cancer | Preclinical |
| (AT009) | Affitech | Cancer | Preclinical |
| CCR4 (KW-0761) | Kyowa Hakko Kirin/Biowa | Cancer, Allergy | Phase 1/2 (Amgen) |
| (AT008) | Affitech | Preclinical | |
| CCR5 (PRO140) | Progenics | Human immunodeficiency virus (HIV) infection | Phase 2 |
| (HGS 004) | Human Genome | HIV | Phase 1 |
| (HGS 101) | Sciences | HIV | Preclinical |
| CCR2 (MLN1202) | Millennium | Inflammation | Phase 2 (Takeda) |
| CCR9 (MLN3126) | Millennium | Inflammation (Crohn disease) | Preclinical (Takeda) |
| CCR8 | ICOS/Eli Lilly | Inflammation | Early stage (patent) |
| GCG-R (AMG477) | Amgen | Type 2 diabetes | Phase 1 |
| GLP-1R | Abbott/Human Genome Sciences | Type 1 or 2 diabetes, neurological/metabolic disease | Early stage |
| VPAC-1 | Thrombogenics | Thrombocytopenia | Preclinical |
| LGR5 | Kyowa Hakko Kirin | Cancer | Early stage (characterization of antibody published) |
| CRTH2 | Sosei/Abgenix | Inflammation | No development recently reported |
| CXCR3 (AT0010) | Affitech | Inflammation | Discovery |
Note: List is not comprehensive. Candidates were identified via examination of sources such as company web sites, press releases, investor-corporate presentations, patent databases and the clinicaltrials.gov web site.